ArticleJournal of thoracic disease2026
Long-term economic value analysis of reducing postoperative air leak following lung resection.
Article in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary air leak (PAL) is one of the most frequent complications following lung resection. While its short-term clinical and economic impacts are well documented, the long-term economic value of interventions that reduce PAL duration remains poorly quantified. This study developed a novel methodological framework to estimate the long-term economic value of PAL reduction and to provide a rapid, quantitative approach for assessing the cost-effectiveness of related clinical interventions. Methods: We developed a hybrid decision-tree-Markov model simulating the natural history and health state transitions following pulmonary resection. Marginal analysis was applied to quantify the relationship between PAL duration (in days) and long-term costs (from both societal and healthcare system perspectives) as well as health outcomes measured in quality-adjusted life years (QALYs). Deterministic sensitivity analyses were performed on key model parameters to assess robustness. Results: Each additional day of PAL was associated with an increase in long-term societal costs of USD 390.4, healthcare system costs of USD 348.1, and a loss of 0.0087 QALYs. Using a willingness-to-pay (WTP) threshold equivalent to one times China's 2024 per capita GDP (USD 13,447.9), the monetized value of the QALY loss amounted to USD 117.6. Consequently, each 1-day reduction in PAL duration generated a total long-term economic benefit of USD 508.0 from a societal perspective and USD 465.7 from a healthcare system perspective. Sensitivity analyses confirmed the stability of these estimates across plausible parameter ranges. Conclusions: This study provides the first quantitative estimation of the long-term economic value of reducing PAL duration after lung resection. The derived marginal values offer a practical, evidence-based tool for rapidly evaluating the economic rationale of PAL-targeted interventions and can inform clinical decision-making, health technology assessment, and policy development in thoracic surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.